<DOC>
	<DOCNO>NCT02887534</DOCNO>
	<brief_summary>A phase 2 randomized clinical trial evaluate efficacy safety SPARC1401 three dose level patient acute low back pain</brief_summary>
	<brief_title>Evaluation Efficacy Safety SPARC1401 Acute Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<criteria>Gives inform write consent able comply study assessment schedule protocol Males females age 18 80 year ( inclusive ) . Female subject surgically sterile ( bilateral tubal ligation least 6 month prior randomization , bilateral oophorectomy hysterectomy perform ) childbearing potential , willing practice acceptable method birth control screen completion study . Subjects consider eligible trial base medical evaluation , electrocardiogram laboratory value screen , laboratory value outside normal range consider clinical significance investigator History presence clinically significant uncontrolled cardiovascular , respiratory , neurological , psychiatric , hepatic , renal , gastrointestinal , hematological , sleep disorder History clinical sign symptom suggestive stenosing peptic ulcer , pyloroduodenal obstruction , inflammatory bowel disease History diagnosis cancer within 5 year prior screen History narrowangle glaucoma , symptomatic prostatic hypertrophy , bladderneck obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>